Antidepressant prescribing for adult people with an intellectual disability living in England
dc.contributor.author | Branford, D | |
dc.contributor.author | Shankar, Rohit | |
dc.date.accessioned | 2022-03-07T10:44:11Z | |
dc.date.available | 2022-03-07T10:44:11Z | |
dc.date.issued | 2022-08 | |
dc.identifier.issn | 0007-1250 | |
dc.identifier.issn | 1472-1465 | |
dc.identifier.other | PII S0007125022000344 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/18893 | |
dc.description.abstract |
<jats:p>The prescribing of psychotropic medications for people with an intellectual disability has changed. In many locations across England, antidepressants have become the most widely prescribed psychotropic. In the context of the current NHS England STOMP programme to reduce inappropriate psychotropic prescribing for people with intellectual disability, there is an urgent need to understand whether this change reflects evidence-based use of the medications involved. There has been little analysis into the benefits or problems associated with the change and whether it is of concern. This paper offers a variety of possible explanations and opportunities to improve clinical practice and policy.</jats:p> | |
dc.format.extent | 488-493 | |
dc.format.medium | ||
dc.language | en | |
dc.language.iso | eng | |
dc.publisher | Royal College of Psychiatrists | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Antidepressants | |
dc.subject | developmental disorders | |
dc.subject | intellectual disability | |
dc.subject | information technologies | |
dc.subject | polypharmacy | |
dc.title | Antidepressant prescribing for adult people with an intellectual disability living in England | |
dc.type | journal-article | |
dc.type | Journal Article | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000765588400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 2 | |
plymouth.volume | 221 | |
plymouth.publication-status | Published | |
plymouth.journal | The British Journal of Psychiatry | |
dc.identifier.doi | 10.1192/bjp.2022.34 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Users by role | |
dc.publisher.place | England | |
dc.identifier.eissn | 1472-1465 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1192/bjp.2022.34 | |
rioxxterms.licenseref.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
rioxxterms.type | Journal Article/Review |